CNBC's Meg Tirrell reports on what's driving the biotech sector to a possible breakout. The “Fast Money” traders weigh in.
Goldman Sachs added biotech company Biogen to its Americas Conviction List, citing a 'blockbuster' drug.
Research analyst Terence Flynn added Biogen to Goldman Sachs' Americas Conviction List on optimism its Alzheimer's drug may be the first to successfully slow the progression of the disease.
The Biotech Goldman Sachs Loves
CNBC's Meg Tirrell reports on Eli Lilly beating on earnings as the stock dips almost 4% and Biogen pops on an earnings beat.
Dow futures jumped on Tuesday, boosted by earnings reports that largely beat Wall Street expectations.
The busiest week for earnings kicks off on Monday, and investors are eyeing one group in particular: biotech.
CNBC's Seema Mody reports on some highs in the biotechnology sector.
Some strategists forecast the group could see further upside as one popular exchange-traded fund just broke through a round-numbered level.
Picks of Steel
One of Stephanie Link's Picks Jumps 10 percent
Some of the names on the move ahead of the open.
These are the stocks posting the largest moves after the bell.
CNBC's Meg Tirrell reports the latest from the Vertex Pharmaceuticals earnings call. The "Fast Money" traders weigh in on trading the pharma and biotech space.
U.S. stock index futures pointed to a higher open on Tuesday as several large-cap companies reported better-than-expected quarterly results.
Samsung Bioepis has won regulatory approval for key biosimilar drug, the first time the company's product has been approved for U.S. use.
South Korea's Samsung Bioepis wins U.S. FDA nod for biosimilar of J&J's Remicade.
CNBC's Meg Tirrell discusses what healthcare investors should expect from the biotech sector. With the "Fast Money" traders.
Increases in the prices of drugs added $8.7 billion to 2016 net income for 28 companies analyzed, accounting for 100 percent of earnings growth last year.
Data covering the past five administrations show that Trump has enjoyed a relatively good, and surprising, market in his first 100 days.